FOXP3 and liver cancer: Ma et al. (56) indicates that 1.13 mg/kg HSYA can modulate the immune microenvironment in liver cancer model mice by decreasing splenic Treg cells and the expression of FOXP3 and RORγt in tumor tissues, thereby enhancing immunity and mitigating cisplatin side effects, contributing to its anticancer effects.